Automate Your Wheel Strategy on ALEC
With Tiblio's Option Bot, you can configure your own wheel strategy including ALEC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALEC
- Rev/Share 0.8083
- Book/Share 0.7091
- PB 3.2012
- Debt/Equity 0.5547
- CurrentRatio 3.7838
- ROIC -0.479
- MktCap 229751240.0
- FreeCF/Share -2.1521
- PFCF -1.0636
- PE -1.9763
- Debt/Assets 0.1108
- DivYield 0
- ROE -1.1206
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ALEC | Mizuho | Neutral | Outperform | -- | $3.5 | July 28, 2025 |
| Downgrade | ALEC | Mizuho | Outperform | Neutral | $9 | $2.5 | Dec. 17, 2024 |
| Downgrade | ALEC | Stifel | Buy | Hold | -- | $4 | Dec. 16, 2024 |
| Downgrade | ALEC | BofA Securities | Neutral | Underperform | $9 | $1 | Dec. 4, 2024 |
News
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.
Read More
Alector to Participate in Upcoming Healthcare Conferences
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m.
Read More
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth …
Read More
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
Read More
Alector to Participate in Upcoming Healthcare Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:
Read More
About Alector, Inc. (ALEC)
- IPO Date 2019-02-07
- Website https://www.alector.com
- Industry Biotechnology
- CEO Arnon Rosenthal
- Employees 175